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Recently we reported (Mehra et al., 2013), that lung granulomas from Mycobacterium bovis Bacille
Calmette–Guérin (BCG)-vaccinated cynomolgus macaques exhibit upon challenge with M. tuberculosis
a more balanced expression of a- and b-chemokines, relative to comparable samples from sham-
vaccinated animals by comparative transcriptomics. Here, we studied the recruitment of immune cells
to blood and lungs in M. tuberculosis-infected macaques as a function of prior BCG-vaccination.
Vaccination initially enhanced the levels of both macrophages and lymphocytes in blood. In contrast,
signiﬁcantly more CD4+ lymphocytes were later recruited to the lungs of sham-vaccinated animals
compared with earlier times/BCG vaccinated animals. BCG-vaccination had a short-lived impact on the
anti-M. tuberculosis response. M. tuberculosis continued to replicate in the lung even in the wake of
increased CD4+ T cell recruitment to primate lungs, indicating that immune subversive mechanisms
are key to its survival in vivo.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Tuberculosis is responsible for the death of over 1.5 million
people every year [1]. This situation has worsened due to the
emergence of drug-resistance [2], HIV co-infection and the
insufﬁcient protection of the Bacillus Calmette–Guérin (BCG)
vaccine, which is unable to protect adults against pulmonary TB
[3,4]. The efﬁcacy of BCG in protecting against adult pulmonary
TB is unsatisfactory [5]. New and efﬁcacious vaccines against TBare therefore urgently needed [6,7]. This requires both a better
understanding of the correlates of protection in appropriate
experimental models [8,9], and also a clearer understanding of
the shortcomings of BCG such that they can be avoided with future
vaccine design.
Nonhuman Primates (NHPs), such as rhesus [10–13] or cyno-
molgus [11,14] macaques are excellent models of Mycobacterium
tuberculosis (Mtb) infection [15]. Upon experimental infection via
either the intrabronchial or the aerosol route, these animals
recapitulate the entire breadth of the human TB infection
syndrome, including acute TB [10] characterized by massive
caseous immunopathology [13] and asymptomatic, latent infection
(LTBI). Furthermore, in macaques, LTBI can be reactivated by SIV
co-infection [12], TNFa inhibition [12,16] or CD4-depletion [17].
More importantly, macaques demonstrate a spectrum of lung
pathological outcomes upon experimental infection with Mtb,
similar to naturally infected human beings [10–13,15,18–20]. Akin
to humans, vaccination with BCG can protect NHPs against Mtb
challenge, but the protection is incomplete [11,21,22]. These obser-
vations reinforce our contention that macaques best represent the
human TB infection syndrome, allowing a study of pathology as
well as protective responses not possible in other model systems
[23].
It is known that prior BCG vaccination leads to a higher expres-
sion of b-chemokines in lung lesions following Mtb challenge [11].
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kines in lung granulomas at week 5, relative to unvaccinated NHPs,
which only expressed high levels of a- but not b-chemokines.
Unsurprisingly, more macrophages were present in the lesions of
vaccinated relative to sham-vaccinated macaques at earlier time
points, as many b-chemokines promote speciﬁc monocyte/macro-
phage chemotaxis.
We reasoned that the presence of signiﬁcantly more macro-
phages in the lesions of BCG-vaccinated primates causes a more ro-
bust antigen-presentation against the pathogen resulting in the
generation of a more effective adaptive immune response. Here
we compared both systemic and local cellular responses to Mtb
infection in the two groups of BCG and sham vaccinated-NHPs by
phenotyping for effector cells in blood, broncho-alveolar lavage
(BAL) and in granulomatous as well as non-granulomatous regions
of the lung at necropsy.Materials and methods
Animals, vaccination, challenge, sample collection and phenotypic
analyses of immune cells
Blood and BAL samples were obtained from BCG- and sham-
vaccinated cynomolgusmacaques (2/group), whichwere challenged
with highly virulent Mtb Erdman 17 weeks post-vaccination [11].
Lung (granuloma as well as adjoining normal) samples were
obtained from necropsy of two animals each in both groups at week
5 and 10 post-infection, a cellular fraction obtained by suspending
the tissue samples in complete Roswell Park Memorial Institute
(RPMI) medium containing collagenase and proteinase-K (1 h,
37 C) and immunophenotyped as described [18]. The experimental
design and the schedule/intervals at which the various blood, BAL
and lung samples were collected for immunophenotyping are
shown in Fig. 1. For ﬂow cytometry, cells were stained with appro-
priately diluted concentrations of speciﬁc monoclonal antibodies
are shown in Table 1.Table 1
List of antibodies used for FACS analysis.
Antibody Fluorochrome Cat# Company Volume used
per reaction (ll)
CD8 PE-TR MHCD0817 Caltag 3
CXCR4 PE-Cy5 555975 BD Biosciences 20
CD4 PerCP-Cy5.5 552838 BD Biosciences 10
CD14 AL700 557923 BD Biosciences 10
CD69 APC Cy7 557756 BD Biosciences 5
CD3 PB 558124 BD Biosciences 7
CASP3 AL647 558124 BD Biosciences 20
CD68 FITC F7135 Dako 20
CD163 PE 556018 BD Biosciences 20
Pre-
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Weeks post-vaccinaon
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Infecon
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Fig. 1. Vaccination, challenge and sampling schedule. Cynomolgus macaques were
divided into two groups (BCG- and sham-vaccinated control) of four per group as
follows: Animals Group 1: IF16 & IF21 (BCG, TB + 5 weeks); IF23 & IF18 (saline,
TB + 5 weeks). Animals Group 2: IF20 & IF17 (BCG, TB + 10 weeks); IF19 & IF22
(saline, TB + 10 weeks). Groups 1 and 2 were sacriﬁced after 5 and 10 weeks post-
challenge with Mycobacterium tuberculosis Erdman (250–500 CFU, bronchoscopi-
cally), respectively. Whole blood (), BAL () and lung (
Q
) samples were collected at
indicated time points.Data evaluation and statistical analysis
Data was analyzed using FlowJo version 9.5.2 and statistical
comparisons utilized ONE-way ANOVA with Bonferroni multiple
hypothesis correction within GraphPad Prism, a P value of <0.05
was considered signiﬁcant.Results
Recruitment of macrophages in peripheral blood and lungs in response
to Mtb infection in BCG-vaccinated and sham-vaccinated NHPs
Signiﬁcantly more macrophages (CD14+ CD68+) were recruited
to peripheral blood of BCG vaccinated compared to sham-vacci-
nated NHPs at an early stage (week 3) post-Mtb infection
(Fig. 2A). This is consistent with our earlier report [11] that more
macrophages are present within early granulomatous lesions de-
rived from BCG-vaccinated rather than sham-vaccinated NHPs.
The increase in blood macrophages is possibly, in part due to in-
creased trafﬁcking of these cells to the lungs of vaccinated animals.
That observation, using confocal microscopy, is itself consistent
with our transcriptomics data, where TB lesions derived from
BCG-vaccinated, Mtb-challenged animals expressed greater
amounts of CCL2 and CCL3 (molecules primarily responsible for
macrophage recruitment) at week 5 [11] but not at the later
time-points. The timing of the immunophenotyping observations
was also consistent with the chemokine expression data. Similarly,
our immunophenotyping data also indicates that while early on (at
week 3), more macrophages were recruited to the lungs of animals
that received vaccination, by the later time point (week 5), the
higher recruitment of macrophages to the lung of vaccinated ani-
mals dissipated and in fact more macrophages were recruited to
the lungs of sham vaccinated animals. It is important to note that
Mtb replication levels, while undetectable for the ﬁrst few weeks,
were signiﬁcantly higher in the sham-vaccinated animals relative
to the BCG-vaccinated animals at the latter time-point (week 5).
Thus, the higher macrophage recruitment levels in the sham-vacci-
nated animals at week 5 could be attributed to differences in anti-
gen load. Monocytes generated in bone marrow enter the
peripheral blood and in response to the appropriate chemotactic
signal home to lungs where they differentiate into activated mac-
rophages that can recognize and begin innate phagocytosis of Mtb.
Thus, one of the mechanisms by which BCG vaccination may confer
partial protection againstMtb infection may be via increased accu-
mulation of innately activated macrophages.Recruitment of lymphocytes in peripheral blood and lungs in response
to Mtb infection in BCG-vaccinated and sham-vaccinated NHPs
Granuloma formation requires the interplay between both in-
nate and adaptive immunity. Hence, we analyzed the recruitment
of T cells followingMtb-infection as a function of vaccination. NHPs
in the BCG-vaccinated group exhibited a signiﬁcant increase in the
peripheral blood levels of total CD3+, CD3+CD4+ and CD3+CD8+ cells
at 3 weeks post-infection (Fig. 2B–D). By week 5, the total number
of CD3+, CD4+ and CD8+ T cells present in the peripheral blood of
sham-vaccinated NHPs were higher than in the vaccinated NHPs
and the differences were no longer statistically signiﬁcant
(Fig. 2B–D), although there remained more T cells in the vaccinated
group. The absolute lymphocyte counts further increased at later
time-points in the unvaccinated (week 7 and 9) (data not shown).
We also analyzed if CD4+ cells from the vaccinated group also
exhibited a higher level of activation, as determined by the co-
expression of CD69 (week 8) as well as CD28 and CD95 (week 3
and 8) (data not shown). Distinct populations of T cells were typed
Fig. 2. Accumulation of macrophages and lymphocytes in whole blood following
Mtb infection as a function of prior BCG vaccination. Absolute cell counts in whole
blood are shown (on Y-axis) for BCG-vaccinated (red) and sham-vaccinated (blue)
NHPs. The numbers on the X-axis indicate weeks prior to or post-Mtb infection. (A)
CD68+ macrophages in whole blood. (B) CD3+ cells, (C) CD3+CD4+ cells, (D)
CD3+CD8+ cells in whole blood. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. Accumulation of macrophages and lymphocytes in lung samples, following
Mtb infection as a function of prior BCG vaccination. Absolute cell counts in BAL
samples are shown (on the Y-axis) for BCG-vaccinated (red) and sham-vaccinated
(blue) NHPs. X-axis in all cases represents time post-Mtb challenge. Thus, a time-
point denoted as 3 corresponds to a post-vaccination time-point 3-weeks prior to
Mtb challenge. (A) CD3+ cells. (B) CD3+CD4+ cells. (C) CD3+CD8+ cells. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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CD95+) or effector memory (CD28CD95+) phenotypes. However,
we were unable to detect any signiﬁcant differences in these sub-
populations between the vaccinated and the sham-vaccinatedgroup. Our results showing a higher absolute recruitment of
CD4+ T cells in the absence of any increase in their activation levels
indicates that BCG vaccination allows for an earlier recruitment of
potentially antigen-speciﬁc T cells upon Mtb infection. This may
potentially represent another possible mechanism by which BCG
partially protects against TB.
While signiﬁcantly more lymphocytes were present in whole
blood immediately following infection, a different result was ob-
served in lungs. In BAL, signiﬁcantly higher numbers of CD3+,
CD4+ and CD8+ T cells were obtained from sham-vaccinated rather
than BCG-vaccinated NHPs at all times observed (weeks 3, 5 and 8)
post-Mtb infection (Fig. 3). Hence, the recruitment of lymphocytes
to the lung occurred largely in an antigen-dependent manner, as a
higher Mtb load was prevalent in the lungs of sham- rather than
BCG-vaccinated macaques.
Next, we analyzed the total number of lymphocytes and their
activation status in the lung lesions derived from the two groups
of animals, relative to adjoining non-lesion areas. At week 5, a
statistically signiﬁcant higher number of CD4+ T cells were present
in the lung lesions derived from sham-vaccinated, relative to
Fig. 4. CD4+ T cells expressed as a % of total lymphocytes are shown for lung (granuloma as well as non-granuloma) samples on the Y-axis for BCG-vaccinated (red) and sham-
vaccinated (blue) NHPs at both 5 (A) and 10-week (B) post-Mtb infection. CD8+ T cells expressed as a % of total lymphocytes are shown for lung (granuloma as well as non-
granuloma) on the Y-axis for BCG-vaccinated (red) and sham-vaccinated (blue) NHPs at both 5 (C) and 10-week (D) post-Mtb infection. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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week 5, was restricted to the granulomatous lesions, because the
CD4+ T cell counts were not different in normal tissue isolated from
lung regions adjoining granulomatous lesions (Fig. 4A). We con-
clude that at this time, the T cells being recruited in an antigen-
speciﬁc manner were speciﬁcally routed to the granuloma. These
differences increased in both magnitude and signiﬁcance in le-
sions, but not in normal tissue at week 10 (Fig. 4B). We also ana-
lyzed the total CD8+ T cell levels in these samples and observed
no differences between the BCG vaccinated and sham-vaccinated
animals and between granuloma and adjoining tissue at either 5
or 10 weeks (Fig. 4C, D). Thus, the excess recruitment of T cells,
in response to the higher replication ofMtb in the sham-vaccinated
group, only manifested itself in the case of CD4 T cells.
Discussion
Long-term control of TB requires the development of efﬁcacious
vaccines [24]. This in turn requires an understanding of the immune
responses that have the potential to protect against increasingly
virulent Mtb infections. The outcome of infection with Mtb – acute
TB, latent infection or reactivation, is decided at the level of the
granuloma [25,26].
Primate granulomas exhibit highly organized architecture,
commonly with central necrosis surrounded by a peripheral rim
of ﬁbrosis [11,18]. This is critical for containing Mtb replication,
and conversely, permitting the latent survival of the pathogen
[27,28]. Recently, it has been proposed that Mtb may actively pro-
mote granulomatous inﬂammation as part of its life cycle, since
granulomas allow it to persist and disseminate [29–31]. However,Mtb must manage this Th1 response through novel mechanisms
[32,33]. Hence, we characterized the cellular response in NHP
granuloma’s, as an addendum to characterization at the molecular
level [11,13,18] and compared it to that observed in blood and
BAL.
Vaccinated animals initially recruited signiﬁcantly higher num-
bers of macrophages, as well as CD3+ and CD3+CD4+ lymphocytes in
peripheral blood upon Mtb challenge, relative to sham-vaccinated
animals. However, these differences rapidly normalized and by
5 weeks post-Mtb infection, higher lymphocyte recruitment oc-
curred in sham-vaccinated animals, in an antigen load-dependent
manner. Moreover, immunophenotyping of both lung tissue and
BAL showed higher CD4+ T cell counts in sham-vaccinated relative
to BCG-vaccinated macaques during early time-points (Fig. 2). The
differences manifested themselves primarily in the granulomatous
lesions obtained from sham-vaccinated relative to BCG-vaccinated
macaques at week 5 and further increased at week 10. The differ-
ences were not observed for the surrounding non-granulomatous
normal tissue andwere speciﬁc to lesion tissue only. Signiﬁcant dif-
ferences were also not observed for CD8+ T cells at either 5 or
10 weeks. Thus, recruitment and accumulation of likely antigen-
speciﬁc, Th1-type, activated CD4+ T cells in granulomatous lesions
occurred as a function of antigen load. However, the accumulation
of these CD4+ T cells in the granulomas of sham-vaccinated NHPs
failed to check both the replication of Mtb and the onset of acute
TB at this site [11].
Since CD4+ T cells are absolutely required for the protective im-
mune response to Mtb infection [34], our results suggest that their
recruitment to the lung by itself is insufﬁcient in controlling the
infection. This underscores the ability of Mtb in modulating host
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responses.
One mechanism by whichMtbmay survive in lungs is by induc-
ing IDO, which encodes indoleamine-2,3,-dioxygenase. Its expres-
sion is highly induced in lungs following Mtb infection in an
antigen-speciﬁc manner and occurs exclusively within macro-
phages in the inner part of the granuloma closer to the central ne-
crotic region [11]. Since IDO exerts powerful T cell suppressive
effects, this expression pattern could prevent activated T cells from
accessing the central regions of the granuloma, potentially pre-
venting the exacerbation of immunopathology. A similar mecha-
nism has been uncovered in lung granulomas formed by Listeria
monocytogenes infection [35].
While preventing immunopathology, IDO may also inadver-
tently provide Mtb with a way to survive in the face of activated
CD4 cells, by forming a physical barrier. This likely allows distance
to be maintained between macrophages infected with Mtb, and
CD4+ cells capable of eliminating the pathogen. Antigens secreted
by the necrosis of macrophages infected with Mtb potentially
causes increased lymphocyte inﬂux to the lesion, but the expres-
sion of IDO around the ring-wall prevents them from directly
engaging Mtb. Hence, an increased antigen-speciﬁc CD4+ T cell re-
sponse in the sham-vaccinated NHPs is unable to check Mtb repli-
cation in NHP lung granulomas. Removal of IDO by inhibitors or
siRNA, or the removal of T cells from this microenvironment,
may in fact overcome this inhibitory effect. Experiments are under-
way to address this question. In this regard, it is important to point
to the work by Rubin and coworkers [36], who recently found that
Mtb can in fact synthesize tryptophan, thus countering the im-
mune-function of IDO in the granuloma.Conﬂict of interest
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